KFP H020
Alternative Names: H-020; KFP-H020Latest Information Update: 07 Oct 2021
Price :
$50 *
At a glance
- Originator Jiangsu Carephar Pharmaceutical
- Class Amino sugars; Antihyperlipidaemics; Drug conjugates; RNA
- Mechanism of Action PCSK9 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hypercholesterolaemia
Most Recent Events
- 28 Sep 2021 Preclinical trials in Hypercholesterolaemia in China (Parenteral) before September 2021 (Jiangsu Carephar Pharmaceutical pipeline, September 2021)
- 28 Sep 2021 Jiangsu Carephar Pharmaceutical plans to submit IND application in Hypercholesterolaemia in China and USA in 2022 (Jiangsu Carephar Pharmaceutical website, September 2021).